238 related articles for article (PubMed ID: 33716974)
21. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
22. Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
Laschinsky C; Theurer S; Herold T; Rawitzer J; Weber F; Herrmann K; Brandenburg T; Führer-Sakel D; Fendler WP; Weber M
J Nucl Med; 2023 Dec; 64(12):1865-1868. PubMed ID: 37884333
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
24. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
25. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
28. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower
Meng Z; Matsuse M; Saenko V; Yamashita S; Ren P; Zheng X; Jia Q; Tan J; Li N; Zheng W; Zhao L; Mitsutake N
IUBMB Life; 2019 Jul; 71(7):1030-1040. PubMed ID: 31026111
[TBL] [Abstract][Full Text] [Related]
30. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
31. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
33. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
34. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
35. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
36. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
37. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
38. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
[TBL] [Abstract][Full Text] [Related]
40. MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS.
Malik N; Nikitski AV; Klam E; Hunt J; Witt B; Chadwick B; Nikiforov YE; Abraham D
Endocr Pract; 2019 Dec; 25(12):1255-1262. PubMed ID: 31412230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]